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Australian Biotechnology Stock Market
Australian Stock Exchange (ASX) Limited (ABN 98 008 624 691) operates Australia's primary national stock exchange for equities, derivatives and fixed interest securities. In addition, it provides a comprehensive set of market data and information on the Australian stock market, share prices, announcements and investments (1) . Table 1 summarizes the market capitalization of listed biotechnology companies on ASX (2) . Before investing in Australian biotechnology companies, it is important to have a clear understanding of the risks of investing in high tech/high growth sectors. Within the Australian biotechnology sector, there is a considerable range of risk profiles among the companies. The levels of risks are determined by a number of factors including the nature of the company's technology, products or services and the stage of development of the products. The points to consider when valuing Australian biotechnology companies are: stage of development; product pipeline; cash reserve; quality research and development;regulatory considerations; intellectual property, platform technology; markets; senior management and other key staff; and clinical trials (1) .
Australian biotechnology is one of the fastest growing sectors in the Australian economy. It is the top growing biotech sector in Asia Pacific. As of December 2004, Australia has approximately 400 biotechnology companies and approximately 560 medical device companies (3) (4) (5) . This places Australia sixth in the world in terms of the number of bitoech companies. As at 30 January 2006, 134 biotechnology and medical devices companies are listed on the ASX. Australian biotechnology industry is slowly maturing. It is firmly "open for business" with a rich source of innovation and commercial opportunities. It is definitely turning heads in all major markets including Asia Pacific (5) . 
Disclaimer
The Authors compiled this article based on the information found in the references and, in the reports and websites of the Australian Stock Exchange (ASX) and Department Industry Tourism and Resources, Australian Government. In some instances, secondary reference source was cited as the primary source could not be accessed. The contents of this article are not meant to constitute professional financial or other advice and any persons should seek their own competent professional financial and other advice. The authors of this article accept no liability whatsoever for any loss to any person resulting from the use of this material.
Average market capitalization $million 194.82
Median market capitalization $million 23.86
Total number of companies 134
